Bioceres Crop Solutions Corp. (BIOX) — Earnings Call X-Ray
Our AI read all 20 of BIOX's earnings calls (2020–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
D
Q2 2025
Calls Analyzed
20
2020–2025
Call-by-call analysis
🔒 Q3 2025 earnings call
2025-05-21
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q3 2025 call grade is ready
The full 37-point AI read of BIOX's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
D
Q2 2025 earnings call
2025-02-12
move ±14%
Management lowered guidance against slowing demand and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: loweredDemand: slowingMargins: expandingPricing: under pressureHeadcount: cuttingCapex: decreasing 5 analysts · 13 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubtsHidden segmentCFO dominatesDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q1 2025 earnings call
2024-11-12
move ±10.2%
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: mixedMargins: expandingPricing: under pressureCapex: decreasing 4 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growthHidden segmentDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q4 2024 earnings call
2024-09-10
move ±11.6%
Management lowered guidance against mixed demand signals. The delivery was unusually candid, rich in specifics.
Guidance: loweredDemand: mixedMargins: stablePricing: under pressureHeadcount: flatCapex: increasing 5 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Early product, fast growthHidden segmentDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C+
Q3 2024 earnings call
2024-05-14
move ±11.1%
Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: mixedMargins: contractingPricing: under pressure 4 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
From the research question bank
18 more research questions answered NO
B
Q2 2024 earnings call
2024-02-08
move ±13.4%
Management held guidance steady against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: acceleratingMargins: expandingPricing: stable 5 analysts · 14 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B
Q1 2024 earnings call
2023-11-14
move ±13.2%
Management held guidance steady against accelerating demand. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: acceleratingMargins: mixedPricing: stableCapex: increasing 4 analysts · 11 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C+
Q4 2023 earnings call
2023-09-12
move ±10.5%
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: mixedMargins: expandingPricing: stable 5 analysts · 14 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q3 2023 |
2023-05-11 |
B |
maintained | mixed | expanding |
7/9 |
2/9 |
| Q2 2023 |
2023-02-09 |
B |
maintained | mixed | contracting |
8/9 |
2/9 |
| Q1 2023 |
2022-11-13 |
B |
maintained | accelerating | stable |
7/9 |
2/9 |
| Q4 2022 |
2022-09-08 |
B |
maintained | accelerating | contracting |
7/9 |
2/9 |
| Q3 2022 |
2022-05-12 |
B+ |
raised | accelerating | stable |
7/9 |
2/9 |
| Q2 2022 |
2022-02-10 |
B+ |
raised | accelerating | expanding |
7/9 |
2/9 |
| Q3 2021 |
2021-11-10 |
C |
maintained | accelerating | mixed |
6/9 |
3/9 |
| Q4 2021 |
2021-09-09 |
C+ |
none | accelerating | contracting |
8/9 |
2/9 |
| Q3 2021 |
2021-05-14 |
B |
none | accelerating | expanding |
7/9 |
2/9 |
| Q2 2021 |
2021-02-11 |
C+ |
maintained | mixed | stable |
7/9 |
2/9 |
| Q1 2021 |
2020-11-14 |
D |
none | accelerating | expanding |
5/9 |
3/9 |
| Q4 2020 |
2020-09-10 |
B+ |
raised | accelerating | expanding |
7/9 |
2/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of BIOX's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
B
Q4 2022 earnings call
2022-09-08
1 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← BIOVF All “B” companies
BIOYF →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.